IBT completed its pivotal Phase 3 trial for IBP-9414, showing a significant reduction in all-cause mortality but missing primary endpoints. Financials reflect continued R&D investment, with strong cash reserves supporting regulatory and commercial plans.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.